LRRK2 and Parkinson disease: Incorporationof our fumarate motif onto the clinically approved BCR-ABL and c-ABLkinase inhibitor dasatinib, the phosphodiesterase 5 (PDE5) inhibitorsildenafil, the SMARCA2-bromodain ligand 1 used in a previously developedSMARCA2 PROTAC ABCI1 developed by the Ciulli group,32 and the LRRK2 inhibitor HG-10-102-01 that is currentlyunder evaluation for Parkinson’s disease that bears a morpholineexit vector led to the generation of JP-2-227, JP-2-201, JP-2-249,and JP-2-244.